Sign In
Buy NPCE
$12.89
-0.86 (-6.25%)
At Close: Jul 31, 2026
NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business Updates
04:05pm, Wednesday, 08'th Jan 2025
Preliminary unaudited revenue expected to be between $21.0 million and $21.5 million for Q4 2024, and between $79.4 million and $79.9 million for full year 2024
NeuroPace (NPCE) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Wednesday, 25'th Dec 2024
NeuroPace (NPCE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NeuroPace to Present at the 43rd Annual J.P. Morgan Healthcare Conference
04:05pm, Wednesday, 18'th Dec 2024
MOUNTAIN VIEW, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that
NeuroPace to Host Investor Day on January 28th in New York City
04:05pm, Thursday, 12'th Dec 2024
MOUNTAIN VIEW, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that
Wall Street Analysts Think NeuroPace (NPCE) Could Surge 31.47%: Read This Before Placing a Bet
10:55am, Friday, 06'th Dec 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 31.5% in NeuroPace (NPCE). While the effectiveness of this highly sought-after metric is questionable, the posi
NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting
04:05pm, Wednesday, 04'th Dec 2024
RNS System to be featured in over 70 scientific presentations and posters Pre-book a demonstration in the NeuroPace Tech Suite to see the latest innovations of the RNS System which simplify the treatm
NeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut Syndrome
04:05pm, Tuesday, 03'rd Dec 2024
Enrollment and implant procedures completed in NIH funded feasibility study of LGS, a severe and disabling childhood-onset epilepsy Enrollment and implant procedures completed in NIH funded feasibilit
What Makes NeuroPace (NPCE) a New Buy Stock
01:00pm, Monday, 18'th Nov 2024
NeuroPace (NPCE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 54.34%: Here's is How to Trade
11:00am, Monday, 18'th Nov 2024
The mean of analysts' price targets for NeuroPace (NPCE) points to a 54.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys
NeuroPace, Inc. (NPCE) Q3 2024 Earnings Call Transcript
07:59pm, Tuesday, 12'th Nov 2024
NeuroPace, Inc. (NASDAQ:NPCE ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Jeremy Feffer – Investor Relations Joel Becker – Chief Executive Officer Rebecca K
NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates
07:06pm, Tuesday, 12'th Nov 2024
NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.28 per share a year ago.
NeuroPace Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal Epilepsy
04:05pm, Monday, 04'th Nov 2024
The RNS System Post-Approval Study (PAS) is the largest prospective post-approval study in neuromodulation for patients with drug - resistant focal epilepsy
Strength Seen in NeuroPace (NPCE): Can Its 5.1% Jump Turn into More Strength?
09:05am, Monday, 28'th Oct 2024
NeuroPace (NPCE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the r
NeuroPace to Report Third Quarter 2024 Financial Results on November 12, 2024
04:05pm, Tuesday, 22'nd Oct 2024
MOUNTAIN VIEW, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it w
NeuroPace Continues to Strengthen Management Team
04:05pm, Wednesday, 16'th Oct 2024
Appoints experienced people leader as Vice President of Human Resources Appoints experienced people leader as Vice President of Human Resources
